1. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab. Issue 5 (7th January 2022) Authors: Miller, Charles; Kwok, Hanson; Harrow, Paul; Vega, Roser; Seward, Edward; Mehta, Shameer; Rahman, Farooq; McCartney, Sara; Parisi, Ioanna; Lim, Samuel Hsiang; Sharma, Esha; Samaan, Mark A; Bancil, Aaron; Kok, Klaartje Bel; Shalabi, Ahmed; Johnston, Emma L; Katarey, Dev; Taherzadeh, Nina; Murray, ... Journal: Frontline gastroenterology Issue: Volume 13:Issue 5(2022) Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PTU-140 Does a dedicated inflammatory bowel disease (IBD) pharmacist clinic improve patient safety ?. (8th June 2018) Authors: Steel, Alan; Morgan, Helen; Tan, Wei; Marvin, Vanessa; Wahed, Mahmood Journal: Gut Issue: Volume 67(2018)Supplement 1 Page Start: A265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗